Ignite Creation Date:
2024-05-06 @ 7:06 PM
Last Modification Date:
2024-10-26 @ 3:00 PM
Study NCT ID:
NCT05891171
Status:
RECRUITING
Last Update Posted:
2024-05-24
First Post:
2023-05-26
Brief Title:
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Sponsor:
Arcus Biosciences Inc
Organization:
Arcus Biosciences Inc
Study Overview
Official Title:
A Phase 11b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARC-25
Brief Summary:
The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone and in combination with zimberelimab and standard chemotherapy in participants with advanced malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None